Eplontersen,Inotersen
Ionis Pharmaceuticals,Akcea Therapeutics,Astrazeneca
['eplontersen']
the investigational agent eplontersen halted neuropathy disease progression and improved neuropathy impairment and quality of life for patients with hereditary transthyretin-mediated amyloid polyneuropathy in a pivotal phase 3 trial. #aanam #aan2023 
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.